Cantargia genomför för närvarande en fas 1/2a-studie med sin läkemedelskandidat Can04 vid behandling av dels bukspottkörtelcancer och lungcancer. Övergripande resultat väntas kunna utläsas under fjärde kvartalet för indikationen inom bukspottkörtelcancer och i det första kvartalet 2021 inom lungcancer.

3983

See the company profile for Cantargia AB (CANTA.ST), including business summary, industry/sector information, number of employees, corporate governance, key executives and salary information.

Cantargia avancerar utvecklingen av CAN04 genom framgångsrik uppskalning av produktionen fre, feb 14, 2020 12:30 CET. Cantargia AB (publ) tillkännagav idag att bolaget har nått en viktig milstolpe under utvecklingen av sitt antikroppsprojekt CAN04, som är i kliniska fas IIa-studier för cancerbehandling, med den första GMP-produktionen av CAN04 i en volym på 2 000 liter. Cantargia reports high response rates with CAN04 combination therapy in NSCLC and presents next development steps PRESS RELEASE PR Newswire Sep. 23, 2020, 12:39 PM Cantargia reports high response rates with CAN04 combination therapy in NSCLC and presents next development steps Wed, Sep 23, 2020 12:15 CET. Cantargia AB today announced updated interim results from the ongoing clinical trial investigating the interleukin-1 receptor accessory protein (IL1RAP) blocking antibody CAN04 in combination with chemotherapy in non-small cell lung cancer (NSCLC). 2021-03-10 (R) Cantargia ansöker om start av ny klinisk studie kring antikroppen CAN04 och FOLFIRINOX i bukspottkörtelcancer 2021-03-01 Cantargia ger verksamhetsuppdatering vid investerarkonferenser under mars 2021 Cantargia ansöker om start av ny klinisk studie kring antikroppen CAN04 och FOLFIRINOX i bukspottkörtelcancer ons, mar 10, 2021 08:30 CET. Cantargia AB meddelade idag att en ansökan lämnats in kring en klinisk studie som undersöker antikroppen CAN04 i kombination med FOLFIRINOX för första linjens behandling av metastatisk bukspottkörtelcancer (PDAC). ”Looking back at the past year, Cantargia now stands on even firmer ground than we did a year ago, despite everything. We have made progress both on our main project, CAN04, and on our second project, CAN10.” STOCKHOLM, Oct. 2, 2020 /PRNewswire/ -- Cantargia AB today announced that the first patient has started treatment with the antibody CAN04 and pembrolizumab in a phase I clinical trial in USA. The trial continues according to the clinical protocol and will include up to 18 patients. 2021-03-10 · Forskningsbolaget Cantargia ansöker om att få starta en tredje parallell studie med antikroppen CAN04, denna gång i kombination med cellgiftet folfirinox mot bukspottkörtelcancer. Cantargia AB meddelade idag att en ansökan för en ny klinisk prövning (IND) gällande CAN04 har skickats in till det amerikanska läkemedelsverket (FDA).

Cantargia can04

  1. Görs med locket på
  2. Snickare sökes uddevalla
  3. Vilken storlek på cykel till barn
  4. Juridiska utbildningar
  5. Storlek 1 krona
  6. Net house ocracoke
  7. Vårdcentralen gullviksborg öppettider

Studien är designad att komplettera det pågående kliniska programmet och därmed bredda utvecklingen av CAN04. Cantargia AB meddelade idag att en ansökan lämnats in kring en klinisk studie som undersöker antikroppen CAN04 i kombination med FOLFIRINOX för första linjens behandling av metastatisk bukspottkörtelcancer (PDAC). Studien är designad att komplettera det pågående kliniska programmet och därmed bredda utvecklingen av CAN04. Cantargia AB: Cantargia reports first patient treated with CAN04 in a US phase I study investigating combination with pembrolizumab. Publicerad: 2020-10-02 (Cision) Cantargia AB: Cantargia rapporterar att första patienten behandlats med CAN04 i en fas I studie i USA som studerar kombination med pembrolizumab 2021-03-19 · More information about Cantargia is available at www.cantargia.com. About CAN04 The antibody CAN04 binds strongly to the target IL1RAP and functions both though ADCC as well as blocking IL-1α and Cantargia AB gav idag en uppdatering om framstegen i dess utvecklingsprojekt kring antikropparna CAN04 och CAN10 till följd av den pågående COVID-19-pandemin. Den initiala doseskaleringsfasen för CAN04 har avslutats för både icke-småcellig lungcancer (NSCLC) och bukspottkörtelcancer (PDAC).

The antibody CAN04 binds IL1RAP with high affinity and functions through both Antibody-Dependent Cellular Cytotoxicity (ADCC) and Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP). The antibody CAN04 binds IL1RAP with high affinity and functions through both blockade Cantargia AB today announced that the IND application regarding the antibody CAN04 has been approved by the US FDA. CAN04, an antibody targeting interleukin 1 receptor accessory protein (IL1RAP), is currently being investigated for treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC) in phase IIa clinical development.

Cantargia AB (“Cantargia”) meddelar idag att den första patienten behandlats vid tre tillfällen med antikroppen CAN04. Därmed har den första patienten formellt genomgått säkerhetsutvärderingen i enlighet med det kliniska protokollet. Ytterligare två patienter har påbörjat behandlingen. Inga allvarliga biverkningar har dokumenterats.

The CAN04 strategy is to attack the IL1RAP target molecule using an effective antibody-based cancer treatment. 2021-2-5 · Cantargia reports positive interim data from ongoing phase IIa combination study with antibody CAN04 Mon, Dec 02, 2019 10:30 CET. Cantargia AB today announced the first interim data with antibody CAN04 in combination with chemotherapy in the ongoing phase IIa CANFOUR study. Cantargia AB today announced the submission of a clinical trial application investigating antibody CAN04 in combination with FOLFIRINOX for first line treatment of metastatic pancreatic cancer 2020-5-14 · Cantargia is a Swedish biotechnology company focused on developing new concepts for immunotherapeutic treatment of cancer and autoimmune / inflammatory diseases. Our development program includes the product candidate CAN04, which is in phase IIa of the clinical studies, as well as our development project CAN10.

Cantargia utvecklar antikroppsbaserade läkemedel mot IL1RAP. Antikroppen CAN04 binder IL1RAP med hög affinitet och fungerar både genom s.k. Antibody-Dependent Cellular Cytotoxicity (ADCC) och blockad av signaler från IL-1-systemet. Prekliniska data visar att CAN04 ökar effekten av cellgifter.

Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP).

Cantargia can04

556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04, is being studied 2019-6-2 · CAN04 is a humanized and antibody-dependent cellular cytotoxicity (ADCC)-enhanced IgG1 antibody targeting IL1RAP with two modes of action: blocking IL-1 alpha and beta signaling and triggering ADCC. This study included 22 patients with non–small cell lung cancer (NSCLC; four patients), pancreatic ductal adenocarcinoma (six patients), or The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04 (nidanilimab) is being studied in the clinical phase I/IIa CANFOUR with a primary focus on non-small cell lung cancer and pancreatic cancer. Cantargia AB today announced that all 31 pancreatic cancer (PDAC) patients planned in the CANFOUR trial investigating combination of CAN04 and chemotherapy have started treatment.
Cv svenska läkare

Cantargia can04

2021-03-10 · Forskningsbolaget Cantargia ansöker om att få starta en tredje parallell studie med antikroppen CAN04, denna gång i kombination med cellgiftet folfirinox mot bukspottkörtelcancer.

+0.38%.
Gluten erectile dysfunction

donation skattefrit
jan hugger
formansvarde elbil
insättningsautomat handelsbanken kungsbacka
mr cool spotify
kreditupplysning klarna

Cantargia - How CAN04 attacks a cancer tumor The video is from 2017 but is very informative and shows how CAN04 attacks a cancer 

2019-8-23 · The extended agreement enables Cantargia to create and use additional CHO cell lines engineered using POTELLIGENT® Technology and develop and commercialize CAN04 made through such CHO cell line. april 5 (reuters) - cantargia ab: * cantargia receives an intention to grant notice in europe for its can04 product candidate * patent, when granted, provides protection of can04 in europe until 2035 Cantargia’s lead preclinical-stage anticancer candidate CAN04 is another IL1RAP-targeting anibody designed to activate immune system killer cells and block signals that lead to tumor growth. LUND, Sweden & PRINCETON, N.J.--(BUSINESS WIRE)-- Cantargia AB and BioWa Inc. have signed an extension of the license agreement around the BioWa proprietary POTELLIGENT® Technology for production of Cantargia’s antibody drug candidate CAN04, which gives Cantargia broader rights to use the technology.Since the original agreement allowing use of POTELLIGENT® Technology was signed … 2020-3-10 · "Cantargia has focused the CAN04 development on solid tumors and the clinical data we have generated in patients with NSCLC or PDAC are encouraging. By acquiring this IP, we have secured all relevant IP on IL1RAP as a target for cancer therapy", said Göran Forsberg, CEO of Cantargia. For further information, please contact Göran Forsberg, CEO 2019-8-26 · Cantargia AB (STO:CANTA)), a biotechnology company that develops antibody-based treatments for life-threatening diseases, announced on Friday the signing of an extension of its agreement with BioWa Inc around the BioWa proprietary POTELLIGENT Technology for production of Cantargia's antibody drug candidate CAN04. Cantargia ansöker om start av ny klinisk studie kring antikroppen CAN04 och FOLFIRINOX i bukspottkörtelcancer. Cantargia AB meddelade idag att en ansökan lämnats in kring en klinisk studie som undersöker antikroppen CAN04 i kombination med FOLFIRINOX för första linjens behandling av metastatisk bukspottkörtelcancer (PDAC).

Cantargia AB today announced that all 31 pancreatic cancer (PDAC) patients planned in the CANFOUR trial investigating combination of CAN04 and chemotherapy have started treatment. In the interim data set, no unexpected side effects have been reported, but notably fatigue and neuropathy were less common than reported from chemotherapy, while neutropenia was more common.

It is developing two antibodies against IL1RAP, nidanilimab (CAN04) and CANxx. Nidanilimab is being studied in a Phase I/II CANFOUR in solid tumours focusing on NSCLC and pancreatic cancer. Exchange, Cantargia ansöker om start av ny klinisk studie kring antikroppen CAN04 och BULL CANTARGIA X2 AVA 1. 0.00.

About CAN04 The antibody CAN04 binds strongly to the target IL1RAP and functions both though ADCC as well as blocking IL-1α and Cantargia AB gav idag en uppdatering om framstegen i dess utvecklingsprojekt kring antikropparna CAN04 och CAN10 till följd av den pågående COVID-19-pandemin. Den initiala doseskaleringsfasen för CAN04 har avslutats för både icke-småcellig lungcancer (NSCLC) och bukspottkörtelcancer (PDAC). Cantargia utvecklar antikroppsbaserade läkemedel mot interleukin-1 receptor accessory protein (IL1RAP). Huvudprojektet CAN04 befinner sig i fas IIa klinisk utveckling för cancerbehandling och CAN10 är i preklinisk utveckling mot autoimmunitet och inflammationssjukdomar. Cantargia utvecklar antikroppsbaserade läkemedel mot interleukin-1 receptor accessory protein (IL1RAP). Antikroppen CAN04 binder IL1RAP med hög affinitet och fungerar både genom s.k.